/
Other
Memory Impairment
1
Pipeline Programs↗
0
Active Trials↗
2
Companies Involved↗
Memory Impairment is an early-stage landscape with 1 program across 2 companies. The most active players are Shaanxi Micot Pharmaceutical Technology Co., Ltd., Otsuka.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
13
clinical trials
Completed10 · 77%
Unknown status2 · 15%
Terminated1 · 8%
Clinical Trials
Trial Activity
13 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)